Showing 2181-2190 of 5789 results for "".
- Aditxt Forms Adimune, Inc.; Appoints Dr. Friedrich Kapp as Chairman and CEOhttps://practicaldermatology.com/news/aditxt-forms-adimune-inc-appoints-dr-friedrich-kapp-as-chairman-and-ceo/2461479/Aditxt, Inc. has formed Adimune
- Hyphens Pharma Licenses Winlevi for 10 ASEAN Countries from Cosmo Pharmaceuticalshttps://practicaldermatology.com/news/hyphens-pharma-licenses-winlevi-for-10-asean-countries-from-cosmo-pharmaceuticals/2461475/Hyphens Pharma International Limited’s subsidiary Hyphens Pharma Pte. Ltd. has entered into exclusive license and supply agreements with Cassiopea S.p.A to develop and commercialize Winlevi (clascoterone) cream 1% and all future product extensions and/or improvemenst in the treat
- Practical Dermatology® Magazine’s Sister Publication Named Exclusive Media Partner for Octane’s Aesthetics Tech Forum 2023https://practicaldermatology.com/news/practical-dermatology-magazines-sister-publication-named-exclusive-media-partner-for-octanes-aesthetics-tech-forum-2023/2461474/Practical Dermatology’s sister publication, Modern Aesthetics® magazine, is the exclusive media partner for Octane’s Aesthetics Tech Forum 2023.Now in its fourth year, Octane's Aesthetics Tech Forum is a two-day immersive, in-person and digital
- First Participant Randomized in Dermaliq Therapeutic's Phase 1b/2 Trial Evaluating DLQ01 for AAhttps://practicaldermatology.com/news/first-participant-randomized-in-dermaliq-therapeutics-phase-1b2-trial-evaluating-dlq01-for-aa/2461470/The first participant has been randomized in a Phase 1b/2a trial of Dermaliq Therapeutics Inc.’s DLQ01 solution in men with androgenic alopecia. The trial is designed to evaluate the safety, systemic absorption, pharmacodynamics, and clinical efficacy of DLQ01 in men with and
- Immunomic Therapeutics Receives FDA Fast Track Designation for pDNA Vaccine for Skin Cancerhttps://practicaldermatology.com/news/immunomic-therapeutics-receives-fda-fast-track-designation-for-pdna-vaccine-for-skin-cancer/2461468/Vaccine exclusively delivered with the PharmaJet Stratis® Needle-free Injection System
- Endo Removes Qwo from Market Due to Concerns About Injection Site Bruising, Skin Discolorationhttps://practicaldermatology.com/news/endo-removes-qwo-from-market-due-to-concerns-about-injection-site-bruising-skin-discoloration/2461467/Endo International plc is ceasing the production and sale of Endo Aesthetics' Qwo (collagenase clostridium histolyticum-aaes) in light of market concerns about the extent and variability of bruising following initial treatment as well as the potential for prolonged skin discoloratio
- Arcutis Enrolls First Patient in Phase 1b Alopecia Areata Study of ARQ-255https://practicaldermatology.com/news/arcutis-enrolls-first-patient-in-phase-1b-alopecia-areata-study-of-arq-255/2461458/The first subject has been enrolled in a Phase 1b study evaluating Arcutis’ ARQ-255, a topical suspension of ivarmactinib, a potent and specific janus kinase 1 (JAK1) inhibitor, for the treatment of alopecia areata. ARQ-255 has been specifically formulated with Arcutis’
- Study: Eating Grapes May Protect Skin from UV Damagehttps://practicaldermatology.com/news/study-eating-grapes-may-protect-skin-from-uv-damage/2461452/Consuming grapes can protect against ultraviolet (UV) damage to the skin, according to a new study in Antioxidants. Folks showed increased resistance to sunburn after consuming 2 ¼ cups of grapes every day
- Cosmetic Surgery Forum 2022 Kicks Off in Nashvillehttps://practicaldermatology.com/news/cosmetic-surgery-forum-2022-kicks-off-in-nashville/2461451/Now in its 14th year, the 2022 Cosmetic Surgery Forum is once again taking Nashville by storm with new faculty members, a new roundtable, and exciting new topics along with the frank discussions, candor, and live demos that attendees have come to expect. “CSF 2022 is our be
- Dermavant Launches First Commercial for VTAMAhttps://practicaldermatology.com/news/dermavant-launches-first-commercial-for-vtama/2461441/Dermavant Sciences launched its first